More than 100 plaintiffs with cases pending in Pennsylvania federal court over claims that the diabetes drug Invokana caused kidney damage are challenging the drugmaker’s efforts to move those cases into a recently-established multidistrict litigation in New Jersey.
Drugmakers Janssen Pharmaceuticals recently filed a motion seeking to stay and then transfer or dismiss 106 cases that had been filed in Pennsylvania state court and later removed to the U.S. District Court for the Eastern District of Pennsylvania. The plaintiffs responded to those efforts Monday, arguing that the transfer would go against “virtually all of” the factors courts should consider.
